Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Seelos Therapeutics Inc News

    0,2856 $ -5,12% -0,0154 $
    In : 0,2663 € | 25.04.24 22:00:04 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3ESGY
    ISIN: US81577F2083
    US-Symbol: SEEL
    Typ: Aktie

    Seelos Therapeutics Inc News

    14.08.23 - PR Newswire
    Seelos Therapeutics Provides Second Quarter 2023 Clinical Update
    Seelos Therapeutics Provides Second Quarter 2023 Clinical Update PR Newswire
    09.08.23 - PR Newswire
    Thinking about buying stock in T2 Biosystems, Lucid Group, Seelos Therapeutics, Proterra, or Infinity Pharmaceuticals?
    Thinking about buying stock in T2 Biosystems, Lucid Group, Seelos Therapeutics, Proterra, or Infinity Pharmaceuticals? PR Newswire
    22.06.23 - PR Newswire
    Seelos Therapeutics Announces the Close of Enrollment of its Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in Adults with Major Depressive Disorder (MDD)
    Seelos Therapeutics Announces the Close of Enrollment of its Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior ...
    22.05.23 - PR Newswire
    Seelos Therapeutics to Participate in Two Upcoming Healthcare Conferences
    Seelos Therapeutics to Participate in Two Upcoming Healthcare Conferences PR Newswire
    15.05.23 - PR Newswire
    Seelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial Results
    Seelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial Results PR Newswire
    05.05.23 - PR Newswire
    Seelos Therapeutics to Present a Poster on SLS-009 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
    Seelos Therapeutics to Present a Poster on SLS-009 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting PR Newswire
    04.04.23 - PR Newswire
    Seelos Therapeutics Doses the First Amyotrophic Lateral Sclerosis (ALS) Patient with SLS-005 in an Expanded Access Program
    Seelos Therapeutics Doses the First Amyotrophic Lateral Sclerosis (ALS) Patient with SLS-005 in an Expanded Access Program PR Newswire
    29.03.23 - PR Newswire
    Seelos Therapeutics Announces Business Update on its Key Programs
    Seelos Therapeutics Announces Business Update on its Key Programs PR Newswire
    10.03.23 - PR Newswire
    Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock
    Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock PR Newswire
    15.02.23 - PR Newswire
    Seelos Therapeutics to Participate in 43rd Annual Cowen Health Care Conference
    Seelos Therapeutics to Participate in 43rd Annual Cowen Health Care Conference PR Newswire
    13.02.23 - PR Newswire
    Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform
    Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform PR Newswire
    10.02.23 - PR Newswire
    Seelos Therapeutics to Present a Poster on SLS-004 at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit
    Seelos Therapeutics to Present a Poster on SLS-004 at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit PR Newswire
    06.02.23 - PR Newswire
    Seelos Therapeutics Doses First Patients in an Ethnobridging Study with SLS-002 (Intranasal Racemic Ketamine)
    Seelos Therapeutics Doses First Patients in an Ethnobridging Study with SLS-002 (Intranasal Racemic Ketamine) PR Newswire
    22.12.22 - PR Newswire
    Seelos Therapeutics to Participate in the 12th Annual LifeSci Partners Corporate Access Event
    Seelos Therapeutics to Participate in the 12th Annual LifeSci Partners Corporate Access Event PR Newswire
    15.12.22 - PR Newswire
    Seelos Therapeutics Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease
    Seelos Therapeutics Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's ...
    08.12.22 - PR Newswire
    Seelos Therapeutics Releases the Itinerary for its Research and Development Update Conference Call and Webcast to be Held on December 15, 2022
    Seelos Therapeutics Releases the Itinerary for its Research and Development Update Conference Call and Webcast to be Held on December 15, 2022 PR Newswire
    07.11.22 - PR Newswire
    Seelos Therapeutics to Participate in the Guggenheim 4th Annual Immunology and Neurology Day
    Seelos Therapeutics to Participate in the Guggenheim 4th Annual Immunology and Neurology Day PR Newswire
    27.10.22 - PR Newswire
    Seelos Therapeutics to Sponsor and Participate in Wonderland, the World's Leading Psychedelic Event
    Seelos Therapeutics to Sponsor and Participate in Wonderland, the World's Leading Psychedelic Event PR Newswire
    25.10.22 - PR Newswire
    Seelos Therapeutics Doses First Patient in a Registrational Phase II/III study of SLS-005 in Spinocerebellar Ataxia
    Seelos Therapeutics Doses First Patient in a Registrational Phase II/III study of SLS-005 in Spinocerebellar Ataxia PR Newswire
    30.09.22 - PR Newswire
    Seelos Therapeutics to Collaborate with the Healey & AMG Center for ALS in an Expanded Access Program Funded by a Grant from the National Institute of Neurological Disorders and Stroke under the Accelerating Access to Critical Therapies for ALS Act (ACT for ALS)
    Seelos Therapeutics to Collaborate with the Healey & AMG Center for ALS in an Expanded Access Program Funded by a Grant from the National Institute of Neurological Disorders ...

    Newssuche

    Videos

    newspaper
    25.04.24 +21,95%
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: NG8FUZ Hebel: 31 Laufzeit: OpenEnd Einstieg: Market ... Mehr »